Factor VIII and factor V share structural homology and bind to phospholipid membranes via tandem, lectin-like C domains. Their respective C2 domains bind via two pair of hydrophobic amino acids and an amphipathic cluster. In contrast, the factor V-like, homologous subunit (Pt-FV) of a prothrombin activator from Pseudonaja textilis venom, is reported to function without membrane binding. We hypothesized that the distinct membrane-interactive amino acids of these proteins contribute to the differing membranedependent properties. We prepared mutants in which the C2 domain hydrophobic amino acid pairs were changed to the homologous residues of the other protein and a factor V mutant with five amino acids changed to those from Pt-FV (FV MTTS/Y ). Factor VIII mutants were active on additional membrane sites and had altered apparent affinities for factor X. Some factor V mutants, including FV MTTS/Y , had increased membrane interaction and apparent membrane-independent activity that was due to phospholipid retained during purification. Phospholipid-free FV MTTS/Y showed increased activity, particularly a 10-fold increase in activity on membranes lacking phosphatidylserine. The reduced phosphatidylserine requirement correlated to increased activity on resting and stimulated platelets. We hypothesize that altered membrane binding contributes to toxicity of Pt-FV.
Factor VIII and factor V share structural homology and bind to phospholipid membranes via tandem, lectin-like C domains. Their respective C2 domains bind via two pair of hydrophobic amino acids and an amphipathic cluster. In contrast, the factor V-like, homologous subunit (Pt-FV) of a prothrombin activator from Pseudonaja textilis venom, is reported to function without membrane binding. We hypothesized that the distinct membrane-interactive amino acids of these proteins contribute to the differing membranedependent properties. We prepared mutants in which the C2 domain hydrophobic amino acid pairs were changed to the homologous residues of the other protein and a factor V mutant with five amino acids changed to those from Pt-FV (FV MTTS/Y ). Factor VIII mutants were active on additional membrane sites and had altered apparent affinities for factor X. Some factor V mutants, including FV MTTS/Y , had increased membrane interaction and apparent membrane-independent activity that was due to phospholipid retained during purification. Phospholipid-free FV MTTS/Y showed increased activity, particularly a 10-fold increase in activity on membranes lacking phosphatidylserine. The reduced phosphatidylserine requirement correlated to increased activity on resting and stimulated platelets. We hypothesize that altered membrane binding contributes to toxicity of Pt-FV.
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Introduction:
Factor VIII is an essential cofactor for the intrinsic branch of the coagulation cascade. The clinical importance of factor VIII is illustrated by hemophilia A, a disease in which deficient or defective factor VIII leads to a severe clinical bleeding phenotype. Factor VIII has sequence homology with factor V, an essential cofactor for the common final pathway of the coagulation cascade. Complete deficiency of factor V is incompatible with life 1 while a partial deficiency causes a bleeding disorder termed "parahemophilia."
Both factor VIII and factor V bind to membranes containing phosphatidylserine and serve, respectively, as cofactors for factor Xase and prothrombinase enzyme complexes. [2] [3] [4] [5] Excessive activity of the factor Xase 6, 7 and prothrombinase complexes 8 are linked to an elevated risk of thrombosis. The importance of binding to phosphatidylserine-containing membranes is illustrated by nearly complete loss of activity when this interaction is blocked by an antibody 9 or when membrane binding sites are blocked by a competing protein. 10 Similarly, activity is diminished by point mutations that diminish the interaction with phosphatidylserine-containing membranes. 11, 12 There are no reported disorders linked to increased activity related to enhanced membrane binding. The functional consequences of altered membrane binding are the foci of this investigation.
To that end, we also investigated a form of factor V that has less need for phospholipid membranes.
The venom of the eastern brown snake (Pseudonaja textilis) contains a potent prothrombin activating protein complex (pseutarin C) that is homologous to factor Xa bound to factor Va in the prothrombinase complex. 13 Recent results have shown that the factor Va-homologous subunit (Pt-FV) is constitutively active and does not require phospholipid membranes to function. 14 We hypothesized that differences in the membrane-binding region of this subunit contribute to its unusual activity and the ability of pseutarin C to induce massive disseminated intravascular coagulation in the snake's prey.
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Factor VIII and factor V both have domain structures of A1-A2-B-A3-C1-C2 in which the A domains share homology with ceruloplasmin, the B domains are unique to each protein, and the C domains are homologous with the discoidin class of lectins. 16, 17 The C2 domains contain determinants of membrane binding. 18, 19 High-resolution crystal structures have been published for the C2 domains of both factor V 20 and factor VIII. 21 The common feature is a β-barrel core with three relatively long loops protruding from one end. These loops have been dubbed "spikes" and both the factor V C2 domain and the factor VIII C2 domain have 2 water-exposed hydrophobic residues protruding from spike 1 and either two (factor VIII) or one hydrophobic residue (factor V) protruding from spike 3 ( Figure 1 ). This feature led to a hypothesis that membrane binding is mediated by insertion of the hydrophobic residues into the For personal use only. on November 16, 2017. by guest www.bloodjournal.org From membrane. A fourth loop (spike 4) in the C2 domain has also been identified as a possible membraneinteractive region, due to its association with a small-molecule inhibitor of both factor V and factor VIII. 22, 23 Membrane-binding functionality of the hydrophobic residues on spike 1 is illustrated by the presence of mild hemophilia and defective phospholipid binding in patients with a single amino acid deletion near the tip of the loop. 24 The membrane-binding functions of spikes 1, 3, and 4 have been confirmed by site-directed mutagenesis. 11, 12, 25 Membrane binding of factor VIII and factor V is usually modeled as a simple, reversible equilibrium interaction. 2, 26 This interaction is mediated, in part, by stereoselective preference for phosphatidyl-Lserine over other membrane lipids 27, 28 and both proteins bind with dissociation constants in the 1-10 nM range. The crystal structures of factor VIII 37, 38 and inactivated factor V (factor Vai) 39 indicate that the membrane-binding C2 domains are positioned so that they might also make contact with the respective proteases, factor IXa for factor VIIIa, and factor Xa for factor Va. They may also make contact with the respective substrates, factor X for factor VIIIa, and prothrombin for factor Va. 40 Indeed, the Gla domain of factor IXa contacts factor VIII, with the best candidate domains being either the C1 or C2 domain.
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Likewise, the Gla domain of prothrombin makes contact with factor Va. 40 Thus, mutations in the C2 domains could plausibly influence the interaction of either factor VIIIa or factor Va with the respective enzymes and/or substrates.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From This study was motivated by questions about the tolerance for conservative mutations in the membrane-interactive amino acids of the C2 domains of both factor V and factor VIII. Thus, we prepared mutants in which the MF pair from the first membrane interactive loop of factor VIII was swapped for the WW pair at the homologous position of the factor V C2 domain ( Figure 1 ). Likewise, the LL pair, protruding from the second membrane interactive loop of factor VIII, was swapped for the LS pair at the same position in factor V. Complementary swaps within factor V were also prepared (Table 1) . To investigate the activity of factor V from P. textilis venom, five amino acids in the membrane-binding region of factor V were mutated to their corresponding amino acids from Pt-FV ( Figure 5 ). The results indicate that conservative mutations of these hydrophobic amino acids are consistent with maintained overall function. The impact of the mutations appears to influence the number and type of binding sites that support activity, the affinities for the respective substrates, and the degree of allosteric activation on membranes with little or no phosphatidylserine.
Materials and methods:
See Supplemental Materials for materials, details of mutagenesis of full length factor VIII and factor V, purification, and details of factor Xase activity and prothrombinase activity assays. Approval for the use of blood from normal donors (to purify platelets for study) was obtained from the Brigham and Women's Hospital IRB. Subjects signed IRB-approved ICF's as part of the consent process in accordance with the Declaration of Helsinki.
VWF Binding Assay. The affinity of factor VIII for VWF was measured in a competition ELISA.
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Wild type or mutant factor VIII, at 1 unit/ml, was incubated with various concentrations of VWF for 60 min. at 23 ˚C to enable equilibrium binding 42 Subsequently, the factor VIII-VWF mixtures were placed in micro-titer wells coated with mAb B02C11. VWF competes for the mAb B02C11 epitope 9 so that only free factor VIII was available to bind to immobilized mAb B02C11. After 60 min. the wells were washed and bound factor VIII was detected with antibody ESH8, followed by HRP-conjugated goat anti-mouse antibody. The wells were developed with o-phenylenediamine dihydrochloride (Sigma) and read in kinetic mode. Wells without factor VIII were used to obtain background values (which ranged from 5 mAU/min to 16 mAU/min over the experiments performed) that were subtracted from all data points (maximum signal from 77 mAU/min to 89 mAU/min) before further analysis. Samples were diluted with 250 μL buffer immediately prior reading by flow cytometry. Background readings, taken using antibody-coupled beads that were not incubated with factor V or factor VIII, were subtracted from the raw data prior to analysis.
Data Analysis. The competition binding data was interpreted assuming that mAb B02C11 bound all factor VIII that was not bound to VWF. The ELISA data was normalized to the maximum signal in the absence of VWF for each data set and then subtracted from 1 to generate upright binding curves. The data from two experiments was combined and analyzed according to the equation:
Where F is the fraction of factor VIII bound to VWF, Bmax is the maximum achievable concentration of VWF-bound factor VIII, KD is the equilibrium dissociation constant of factor VIII with VWF, FVIII represents the total factor VIII concentration and VWF represents the total concentration of VWF subunits. Data were fitted using Prism 4.0 for the Macintosh.
Data from prothrombinase, factor Xase, and direct lipid-binding assays were fitted by non-linear least squares analysis using the one site-binding function in the Prism 4.0 software package and normalized to the respective Bmax values. The normalized data from multiple factor Xase and prothrombinase experiments were combined and fitted to obtain the values displayed in figures 2C and 3C.
Results:
Factor VIII mutants. We prepared three factor VIII mutants, substituting the hydrophobic spike amino acids of factor V for either and for both of the pairs of hydrophobic spike amino acids of factor VIII ( Figure 1 ; Table 1 ). The mutants, together with wild-type factor VIII (FVIII WT ) were expressed from COS-7 cells and purified by immuno-affinity chromatography. The mutants were evaluated for activity in a commercial aPTT assay and for apparent affinities for phospholipid vesicles, factor IXa, and factor X in a defined factor Xase assay ( Figure 2 ). For all assays, the activity of the mutants was referenced to FVIII WT purified in the same manner for each batch of mutants. The specific activity of FVIII WT averaged (Figure 2A) suggesting that L2252 may make a substantial contribution to binding site interaction. We utilize the term "reactivity" to denote the product of binding site affinity and number of binding sites/phospholipid vesicle since the mutations may affect either or both parameters. The apparent affinity of FVIII LS for factor X was decreased approximately 50% ( Figure 2B ). These results indicate that interaction with factor X is altered by changes in membrane binding or that L2252 interacts directly with factor IXa and/or factor X. The specific activity, membrane reactivity, and apparent affinity of FVIII LS for factor X are displayed as a ratio with FVIII WT in Figure 2C . The unaltered specific activity of FVIII LS may be rationalized with the decreased phospholipid reactivity by noting that the commercial aPTT reagent has a very high phospholipid concentration of unknown composition that may influence results.
Mutant FVIII WW had approximately 2-fold increased specific activity ( Figure 2C ). Correlating with the increased specific activity was an approximately 6-fold increase in phospholipid reactivity. The apparent affinity curves, analogous to those in panels A and B of figure 2 can be found in Suppl Figure 2 .
FVIII WW also had increased apparent affinity for factor X. These results indicate the hydrophobic WW sequence of factor V supports these three components of factor VIII activity with higher affinities than the native MF sequence.
Mutant FVIII WW/LS , incorporating factor V amino acids for both hydrophobic pairs, had normal specific activity ( Figure 2C ). Furthermore, the interaction with phospholipid and apparent affinity for factor X were within 2-fold of FVIII WT . The results indicate that these contacts result from constituent interactions of both hydrophobic spikes that are additive in effect.
Direct binding studies of phospholipid vesicles to immobilized factor VIII (Table 2, Suppl Figure   1A ) indicated that the WW substitution for residues of spike 1 conferred a 2-fold increase in affinity.
This increase is consistent with the increased phospholipid vesicle reactivity ( Figure 2C ). In contrast, the preserved affinity of FVIII LS suggests that the decreased PL interaction observed in the factor Xase complex results from another change, such as functional activity on fewer membrane sites.
Because both hydrophobic spikes of factor VIII affect the affinity for VWF 11 we evaluated the apparent VWF-binding affinities of our mutants ( Figure 2D ). In this assay, the interaction between FVIII WT and VWF was modeled with a K D of 0.7 ± 0.1 nM, similar to previously measured factor VIII-VWF affinity utilizing a similar assay. 11 FVIII WW had 3-fold decreased apparent affinity for VWF, indicating that the increased affinity for phospholipid does not correlate to increased VWF affinity.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From FVIII LS had a 7-fold decreased apparent affinity for VWF, indicating that L2252 in the second hydrophobic spike makes a significant contribution to VWF affinity that is not compensated by interaction with Ser. In the absence of VWF, FVIII WT and FVIII MF showed similar binding to the capture antibody B02C11, while FVIII LS showed approx. half the signal strength and FVIII WW/LS had sufficiently decreased affinity for mAb B02C11 that measurement of apparent affinity for VWF was unreliable (data not shown). These results indicate that the native MF sequence in the first hydrophobic spike has interactions with VWF that are more selective than interactions with phospholipid.
Factor V mutants with factor VIII residues. Wild-type factor V and factor V mutants (Table 1) were expressed from COS-7 cells and purified by ion exchange chromatography. The specific activity of purified FV WT averaged 560 units/mg. Apparent affinities of factor V mutants for factor Xa were not clearly different from wild type factor V and are not shown.
FV LL supported measurable activity of the prothrombinase complex in the absence of phospholipid vesicles ( Figure 3A ). This activity averaged about 20% of the plateau activity when phospholipid vesicles were added. The basis for the phospholipid vesicle-independent activity was further investigated, as described below (Figure 4 ). Furthermore, FV LL had increased phospholipid vesicle reactivity when compared with FV WT. The results indicated that changing S→L in the second hydrophobic spike either increases phospholipid affinity or number of effective binding sites, or the activity of phospholipid-bound factor V.
The apparent affinity of FV LL for prothrombin was increased approximately 2-fold ( Figure 3B ). The specific activity of FV LL was increased approximately 5-fold in a plasma-based factor V activity assay ( Figure 3C ) suggesting that increased phospholipid vesicle reactivity can contribute to increased activity.
Experiments like those depicted in panels 3A and B were utilized to evaluate the affinities of FV MF and FV MF/LL for phospholipid, factor Xa, and prothrombin (Suppl Figure 3) . The results are summarized in Figure 3C . FV MF had phospholipid affinity and factor Xa affinity that was similar to FV WT . However, this mutant supported measurable activity of the prothrombinase complex in the absence of phospholipid vesicles, similar to FV LL . The basis for this is investigated below. The apparent affinity for prothrombin was decreased approx 10-fold. However, the specific activity in a commercial prothrombin time assay remained similar to FV WT .
The specific activity and phospholipid vesicle reactivity of FV MF/LL were increased, similar to FV LL .
Also, FV MF/LL supported prothrombinase activity in the absence of phospholipid vesicles. The affinity for factor Xa was decreased by approximately 50% while the affinity for prothrombin remained similar to FV WT . Thus, the effects of the mutation in the second hydrophobic spike dominated the phospholipid For personal use only. on November 16, 2017. by guest www.bloodjournal.org From interaction and specific activity while the opposing tendencies of the separate mutations were offset with near normal prothrombin affinity.
Phospholipid vesicle-independent activity. We asked whether the phospholipid vesicle-independent activity of factor V mutants ( Figure 3A ) was due to phospholipid that co-purified with factor V from the tissue culture source. Thus, we tested the capacity of these preparations to support activity of the factor Xase complex ( Figure 4A ). The three mutants supported activity of the factor Xase complex in the absence of phospholipid vesicles while FV WT supported little or no activity. There was no measurable activity in the absence of factor VIII indicating that the mutants were not substituting for factor VIII in the factor Xase complex. To confirm that the mechanism of factor Xase support related to phospholipid, we added lactadherin to the factor Xase reactions supported by FV MF ( Figure 4B ). Lactadherin inhibited factor Xase activity confirming that the factor V mutant preparation was contaminated by phospholipid. 10 We next asked whether the contaminating phospholipid could be stripped from the factor V mutants.
Wild-type factor V and mutants were washed with 1% CHAPS detergent (in addition to Tween 80 and PVP-40 already present) prior to elution from the ion exchange column. Mutants prepared in this way no longer supported the factor Xase complex indicating that contaminating phospholipid had been reduced (not shown). However, the mutants prepared in this manner still exhibited a lesser degree of prothrombinase activity without phospholipid vesicles. Thus, we performed further experiments to determine whether the phospholipid vesicle-independent prothrombinase activity of mutants was entirely due to contaminating phospholipid.
Lactadherin efficiently inhibited prothrombinase activity of factor V mutants in the absence of phospholipid vesicles ( Figure 4C ). The extent of inhibition was complete, as judged by the prothrombinase assay. To confirm that phospholipid vesicle-independent prothrombinase activity could be attributed to contaminating phospholipid we evaluated inhibition by phospholipase A 2 ( Figure 4D ).
Control experiments indicated that phospholipase greatly reduced the capacity of phospholipid vesicles to support prothrombinase activity with FV WT (Figure 4D inset) . Addition of phospholipase A 2 to FV LL reduced the capacity to support prothrombinase activity in the absence of phospholipid vesicles. Thus, the capacity of these factor V mutants to support factor Xase activity in the absence of phospholipid vesicles can be attributed to the presence of contaminating phospholipid that co-purifies with mutant factor V.
The factor V mutants were purified with a CHAPS wash for use in direct phospholipid binding assays ( Table 2 , Suppl Figure 1B ). FV LL showed lower lipid affinity than FV WT , while there was no significant difference between FV MF/LL and FV WT . FV MF did not show measurable binding, likely due to insufficient binding of the mutant to the beads. These results indicate that quasi-equilibrium affinity of immobilized factor V mutants for vesicles is comparable to wild type factor V. Thus, the most likely explanation for retained phospholipid is increased importance of the slow phase of dissociation. 43 
Factor V mutants related to Pseudonaja textilis. Because the factor V-like molecule from
Pseudonaja textilis is reported to have membrane-binding properties that are distinct from human factor V we hypothesized that these differences might result from altered membrane-interactive residues of the C2 domain. Sequence alignment of the C2 domains of human factor V, bovine factor V, human factor VIII, and the factor V-homologous subunit from P. textilis venom (Pt-FV), revealed sequence differences in We asked whether FV MTTS/Y might have greater activity on platelets that have little phosphatidylserine exposed on the outer membrane leaflet. After activation by thrombin, platelets Figure   7D ). FV MTTS/Y also supported at least 2-fold more activity on platelets stimulated by thrombin receptor agonist peptide (TRAP). Indeed, the activity of FV MTTS/Y on unstimulated platelets was similar to FV WT on platelets stimulated via TRAP. These results indicate that the MTTS/Y residues of Pt-FV confer the capacity to support increased prothrombinase activity both on vesicles lacking phosphatidylserine and on platelets.
Discussion:
We have found that conservative mutations of the membrane-interactive amino acids of the C2 domains ( Figure 1 ) can enhance as well as diminish function of factor VIII and factor V. The effects of these mutations relate to number of binding sites recognized, membrane affinity, and requirement for PS.
In addition to the changes in membrane interaction for factor VIII and factor V, there were effects on affinity for the respective substrates of the factor Xase and prothrombinase complexes. Further, the mutations altered the linkage between membrane binding and activation of the respective cofactorenzyme complexes. Thus, the results indicate that the specific membrane-interactive amino acids influence co-factor functionality and reversibility of membrane interaction as well as membrane-binding affinity.
The results in this report are in agreement with prior reports evaluating the membrane-interactive roles of amino acids on spike 1 and spike 3. 11, 12 The apparent affinity of immobilized factor VIII for binding sites on phospholipid vesicles ( Willebrand factor interaction has greater specificity for the amino acids of the hydrophobic spikes than the phospholipid membrane sites.
The current results underscore our recent observation that cooperative membrane binding of the factor VIII C1 and C2 domains influences activity of factor VIII as well as membrane binding affinity.
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The prior report indicated that membrane binding of factor VIII via the C1 and C2 domains can be decoupled from full activation of the factor Xase complex. A similar finding for factor V was evident in the current study where FV MTTS/Y had little change in affinity for membranes but 10-fold greater activity in the prothrombinase complex when phosphatidylserine was absent. These results imply that a change in orientation or conformation is linked to membrane binding and confers full cofactor activity.
Our results imply that conservative mutations in the C2 domain can alter membrane-dependent activity of factor VIII or factor V in three ways. First, they can affect membrane affinity or slow membrane dissociation. This is evident with mutants FVIII WW and FVIII WW/LS that have 2-fold increase in membrane affinity vs. the wild-type control. It also appears evident in the factor V mutants that co-purify with phospholipid. Second, the mutations appear to affect binding site specificity. This is evident for mutants FV LL and FV MF/LL . These have preserved affinity for phospholipid vesicles and normal activity in a clotting activity with excess phospholipid. However, they have increased phospholipid interaction, most likely representing capacity to bind and gain full activity on phospholipid binding sites that would not support binding of the respective wild type cofactor. Third, and possibly most interesting, mutant FV MTTS/Y is activated by vesicles that bind wild type factor V but confer a much lower degree of factor V activity. The same property is evident on unstimulated and stimulated platelets, where there is little exposed phosphatidylserine. Further studies will be required to determine whether these properties translate to increased prothrombotic activity in a more complex biological system.
We note an apparent discrepancy between the normal membrane affinities for FV LL , FV MF/LL , and FV MTTS/Y and the capacity of these mutants to retain more phospholipid during purification than FV WT .
We rationalize the apparent discrepancy by noting the slow second phase of membrane dissociation for factor V. 43 Our quasi-equilibrium membrane binding experiments had incubation times long enough to interpret the membrane reactivity of mutant factor V for prothrombinase assays and binding of vesicles to immobilized factor V (Figs 3, 6, Supp Fig 1B, 3A) . However, the incubation times were not long enough to enable the slow phase of dissociation to have its full impact on the measured membrane affinity. Thus, Prior studies indicate that both activated factor V and activated factor VIII, in complex with factor Xa and factor IXa, respectively, are partially activated by water-soluble phosphatidylserine. 34, 35 These data indicated partial decoupling of membrane binding and cofactor activation. Our current report is a counterpart, indicating enhanced coupling of membrane binding and cofactor activation in the absence of PS. Progress in testing hypotheses about this coupling will be enhanced by information about the conformation and dynamics of membrane bound factor VIII or factor V vs. the respective phospholipidfree structures.
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The factor V mutants exhibited phospholipid binding that was not reversible over the time course of purification. The implication is that the dissociation of factor V from COS-7 membrane fragments is slowed to the point where it is not completed during purification. We postulate that this mechanism may have led to retained phospholipid and may have been a contributing factor to the apparent phospholipid independence of recombinant, purified Pt-FV. 14 The persistent phospholipid binding cannot be readily explained by change in hydrophobic surface area because FV MF had diminished hydrophobic surface area compared with FV WT . Our current hypothesis is that dissociation of factor V from a phospholipid membrane is accompanied by the conformational change previously noted in the crystal structures of the factor V C2 domain. 20 The mutations may prevent completion of the conformational change. Regardless of the mechanism, these results indicate that high affinity, reversible membrane binding function of factor V is delicately balanced so that modest changes can interfere with full functionality.
The C2 domains of both factor VIII and factor V undergo conformational changes that are related to Conservative mutations in both the first and third hydrophobic spikes influenced apparent affinities of both the factor Xase complex and the prothrombinase complex for the respective substrates. In both cases, the WW sequence in the first spike led to increased affinity and LL in the second spike led to increased affinities for factor X, and prothrombin, respectively. The mechanism for these changes could relate to altered geometry of the enzyme complex related to the interaction of each spike with the membrane or they could be explained by a direct interaction between the respective hydrophobic spike(s) and the substrates as recently proposed.
37 Further experiments will be necessary to distinguish between these possible explanations.
Our experiments with FV MTTS/Y highlight the potential importance of properties these residues may confer to the membrane binding of Pt-FV. Our results show that these conservative mutations lead to tenacious phospholipid binding leading to retained phospholipid during purification. Retained phospholipid is unlikely to have in vivo significance because P. textilis venom proteins include phospholipases, which seem likely to degrade any retained phospholipid and therefore inhibit corresponding activity. 56 More interesting is the activity of FV MTTS/Y on platelets and membranes lacking PS, a lipid that is normally critical for full factor V function. These results suggest that Pt-FV may be responsible for the ability of pseutarin C to activate prothrombin on cell membranes that would normally not support significant coagulation activity, such as unstimulated platelets.
Our results suggest the possibility that the phospholipid-independent activity attributed to recombinant Pt-FV 14 may actually be due to retained phospholipid. This possibility will likely soon be resolved by experiments such as those in this report. However, our results may also be interpreted while assuming that that the report of Pt-FV phospholipid-independent activity is accurate. Our results suggests that the mutations we identified are not sufficient to allow phospholipid-independent activity even though they allow for prothrombinase activity on membranes that would not normally support it. If the phospholipid-independent activity of Pt-FV is subsequently confirmed, our results indicate that other areas of the protein are likely responsible for this phenomenon. In that case, the membrane binding properties of Pt-FV might still function to localize the fully active prothrombinase-like complex to membrane sites that would not support binding and assembly of the native prothrombinase complex. 
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